Abstract
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Current Cancer Therapy Reviews
Title:Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Volume: 12 Issue: 3
Author(s): Vamsee Torri
Affiliation:
Keywords: Chemotherapy, targeted therapy, basal cell carcinoma, squamous cell carcinoma, nonmelanoma.
Abstract: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the commonest skin malignancies and if diagnosed early have a good prognosis. Conversely, metastatic disease is rarely associated with a very poor prognosis. Locally advanced BCC is also uncommon and may not be amendable to surgery, radiation therapy or photodynamic therapy. The activation of the hedgehog pathway occurs in 90% of BCCs and inhibition of this pathway with well tolerated oral agents has resulted in an important therapeutic option in some patients with locally advanced or metastatic BCC. In contrast, metastatic SCC tends to behave biologically more aggressively and cisplatin based chemotherapy has very limited efficacy.
Export Options
About this article
Cite this article as:
Torri Vamsee, Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer, Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573394713666161229124633
DOI https://dx.doi.org/10.2174/1573394713666161229124633 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of Cytotoxicity of Benzamide Riboside by Expression of NMN Adenylyltransferase
Current Medicinal Chemistry Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Probiotics as a Tool to Biosynthesize Metallic Nanoparticles: Research Reports and Patents Survey
Recent Patents on Drug Delivery & Formulation Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design